Resolving Controversies on the Path to AD Therapeutics
in the Phase 3 trial. However, I also refer to our Nature Reviews Drug Development paper, where I lay
Upcoming Webinars
No Upcoming Webinars AvailableALL WEBINARS
117 RESULTS
You searched papers/many-are-called-yet-few-are-chosen-are-neuropsychiatric-clinical-trials-letting-us-down
Sort By:
- Most Recent
- Most Commented
- Most Relevant
Meet New Players, Histone Deacetylase and Sirtuin—Will They Help the Cell Cycle, DNA Repair, and Gene Expression Break Into Alzheimerology’s Major League?
inactivation. Vikram Khurana Dohoon, Li-Huei, congratulations on the great paper! Cdk5 seems to be a central
Untapped Resource? New Study to Boost Acceptance of CSF Analysis
LP, etc.)? A: This is published in the Nature Rev Neurol paper (see Blennow et al., 2010). Q: We are
Differential Neuronal Vulnerability
(mediated by gene expression differences as shown so well in this paper) to different insults. Once we
Finding NIH Support for Drug Discovery and Development for Neurodegenerative Diseases
Searching for the wherewithal to push on with your work on a promising new Alzheimer therapy? The NIH offers funding for research support at every step of the process, from early drug discovery right through to phase 3 clinical trials, if you know where t
Targeting Tumor Necrosis Factor—A Therapeutic Strategy for AD
Brewer Yong, we have two recent papers that show major effects of TNFR1 and R2 with age in old rat
Microdissection and Microarrays: Analyzing Selective Cell Vulnerability
As Tolstoy wrote in Anna Karenina, “Happy families are all alike; every unhappy family is unhappy in its own way.” The same might be said of the brain. Normal brains look and behave similarly, but those affected by different neurodegenerative diseases are
Probing PPARγ? Agonists: Could Diabetes Drugs Treat Alzheimer's Disease?
Gary Landreth The only data on BBB permeability is contained within a paper on pioglitazone published
Clearing the Fog Around Aβ Oligomers
all papers reporting the effects of aggregated proteins clearly state the exact source of the protein,
Are Neurons Just Too Laissez-Faire about Repair?
paper from Herrup's lab also found that all cases with mild cognitive impairment that were tested
The Pathogen Hypothesis
reported in the paper (you can download a copy of this and other relevant papers). The mouse findings were
Grasping the Shadow Force: Immune Cells in ALS
When two biological networks as complex as the nervous and immune systems cross paths, you know the interaction is not going to be simple. Add in neurodegeneration—such as amyotrophic lateral sclerosis—and it creates a web that will take many scientists t
Not Dead Yet: Estrogen Deserves Another Chance
correct. Mark Smith Phyllis, I have read in several papers otherwise...we should discuss. Sam Gandy I was
Alzheimer's: A Triple Whammy. Why are So Many Neurodegenerative Diseases Single, Double, or Triple Amyloidoses?
Trojanowski If you look at recent work from Goedert and Crowther in PNAS, you will find their paper with
Picking up the Pieces of Parkin
described in the Farrer paper (Farrer et al., 2001) is a partially active mutant as described in our Nature
Have a topic idea for a webinar? We would love to hear it. Send an email to webinars [at] alzforum [dot] org.
Current Filters
- Keyword: papers/many-are-called-yet-few-are-chosen-are-neuropsychiatric-clinical-trials-letting-us-down x